Tolerability of the niraparib individualized starting dose in the PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib first-line maintenance therapy by Vulsteke, Christof, Chambers, Setsuko K., Pérez, Maria Jesús Rubio, Chan, John K., Raaschou-Jensen, Nicoline, Zhuo, Ying, Lorusso, Domenica, Herzog, Thomas J., de la Motte Rouge, Thibault, Thomes Pepin, Jessica A., Braicu, Elena Ioana, Chen, Lee-may, Levy, Tally, Barter, James F., Pilar Barretina-Ginesta, M., Joosens, Eric, York, Whitney, Malinowska, Izabela A., González-Martín, Antonio, Monk, Bradley J.

Get full text

Palbociclib plus letrozole in estrogen receptor-positive advanced/recurrent endometrial cancer: Double-blind placebo-controlled randomized phase II ENGOT-EN3/PALEO trial by Mirza, Mansoor R., Bjørge, Line, Marmé, Frederik, Christensen, René DePont, Gil-Martin, Marta, Auranen, Annika, Ataseven, Beyhan, Rubio, Maria Jesús, Salutari, Vanda, Luczak, Adam A., Runnebaum, Ingo B., Redondo, Andrés, Lindemann, Kristina, Trillsch, Fabian, Ginesta, M. Pilar Barretina, Roed, Henrik, Kurtz, Jean-Emmanuel, Petersson, Karen S., Nyvang, Gitte-Bettina, Sehouli, Jalid

Get full text

Atezolizumab and chemotherapy for advanced or recurrent endometrial cancer (AtTEnd): a randomised, double-blind, placebo-controlled, phase 3 trial by Colombo, Nicoletta, Biagioli, Elena, Harano, Kenichi, Galli, Francesca, Hudson, Emma, Antill, Yoland, Choi, Chel Hun, Rabaglio, Manuela, Marth, Christian, Parma, Gabriella, Fariñas-Madrid, Lorena, Nishio, Shin, Allan, Karen, Lee, Yeh Chen, Piovano, Elisa, Pardo, Beatriz, Nakagawa, Satoshi, McQueen, John, Zamagni, Claudio, Manso, Luis, Takehara, Kazuhiro, Ferrero, Annamaria, Tognon, Germana, Lissoni, Andrea Alberto, Petrella, Mariacristina, Laudani, Maria Elena, Uggeri, Sara, Barretina Ginesta, M Pilar, Casanova, Claudia, Arcangeli, Valentina, Antonuzzo, Lorenzo, Gadducci, Angiolo, Cosio, Stefania, McNeish, Ian, Tookman, Laura, Redondo Sanchez, Andrés, Choi, Chel Hun, Baldini, Editta, Palaia, Innocenza, Benedetti Panici, Pierluigi, Takahashi, Nobutaka, Lombard, Janine, Ardizzoia, Antonio, Bologna, Alessandra, Herrero Ibáñez, Ana Maria, Musolino, Antonino, Márquez Vázquez, Raúl, Pietzner, Klaus, Braicu, Elena, Heinzelmann-Schwarz, Viola A., Powell, Melanie, Yokoyama, Yoshihito, Abeni, Chiara, Cueva, Juan Fernando, Trillsch, Fabian, Ataseven, Beyhan, Petru, Edgar, Heubner, MartinLeonhard, Sadozye, Azmat Hassanq, Dubey, Sidharth, Tiley, Susan, Chrystal, Kathryn, Kim, Sang Wun, Fehr, Mathias, Scatchard, Kate, Anand, Anjana, Taylor, Alexandra, Enomoto, Takayuki, Yoshihara, Kosuke, Selva-Nayagam, Sudarsha, Karki, Bhaskar, Wilkinson, Kate, Chantrill, Lorraine, Lee, Chulmin, Bertolini, Alessandro, Narducci, Filomena, Bellotti, Giovanna, Fusco, Vittorio, Aebi, Stefan, Del Grande, Maria, Tokunaga, Hideki, Shigeta, Shogo, Goss, Geraldine, Siow, Zhen Rong, Steer, Christopher, Lee, Kwang-Beom, Di Meglio, Giovanni, Massa, Elena, De Marino, Elvira, Tortora, Vincenzo, Palacio Vazquez, Isabel, Tsuji, Kosuke, Tominaga, Eiichiro, Black, Allison, So, Kyeong A, Suh, Dong Hoon, Lee, Keun Ho, Fossati, Roldano, Carlucci, Luciano, Barberis, Massimo

Get full text

Use of individualized starting dose and niraparib hematologic adverse event management costs in ovarian cancer by Graybill, Whitney, Vergote, Ignace, Pothuri, Bhavana, Anttila, Maarit, O'Malley, David, Lorusso, Domenica, Haggerty, Ashley, Fabbro, Michel, Chan, John, Heitz, Florian, Willmott, Lyndsay, Bruchim, Ilan, Zhuo, Ying, Estévez-García, Purificación, Monk, Bradley, Denys, Hannelore, Knudsen, Anja, Tinker, Anna, Sánchez, Luis Manso, Provencher, Diane, Barretina-Ginesta, M. Pilar, Hartman, John, Booth, Donna, González-Martín, Antonio

Get full text

INOVATYON/ ENGOT-ov5 study: Randomized phase III international study comparing trabectedin/pegylated liposomal doxorubicin (PLD) followed by platinum at progression vs carboplatin/... by Colombo, N., Gadducci, A., Sehouli, J., Rulli, E., Mäenpää, J., Sessa, C., Montes, A., Ottevanger, N. B., Berger, R., Vergote, I., D’Incalci, M., Churruca Galaz, C., Chekerov, R., Nyvang, G. B., Riniker, S., Herbertson, R., Fossati, R., Barretina-Ginesta, M. P., Deryal, M., Mirza, M. R., Biagioli, E., Iglesias, M., Funari, G., Romeo, M., Tasca, G., Pardo, B., Tognon, G., Rubio-Pérez, M. J., DeCensi, A., De Giorgi, U., Zola, P., Benedetti Panici, P., Aglietta, M., Arcangeli, V., Zamagni, C., Bologna, A., Westermann, A., Heinzelmann-Schwarz, V., Tsibulak, I., Wimberger, P., Poveda, A.

Get full text

Quality-adjusted time without symptoms of disease or toxicity and quality-adjusted progression-free survival with niraparib maintenance in first-line ovarian cancer in the PRIMA tr... by Barretina-Ginesta, Maria-Pilar, Monk, Bradley J., Han, Sileny, Pothuri, Bhavana, Auranen, Annika, Chase, Dana M., Lorusso, Domenica, Anderson, Charles, Abadie-Lacourtoisie, Sophie, Cloven, Noelle, Braicu, Elena I., Amit, Amnon, Redondo, Andrés, Shah, Ruchit, Kebede, Nehemiah, Hawkes, Carol, Gupta, Divya, Woodward, Tatia, O’Malley, David M., González-Martín, Antonio

Get full text

Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial by Gladieff, Laurence, Martínez-García, Jerónimo, Villacampa, Guillermo, Takekuma, Munetaka, De Giorgi, Ugo, Lindemann, Kristina, Woelber, Linn, Colombo, Nicoletta, Duska, Linda, Leary, Alexandra, Godoy-Ortiz, Ana, Angelergues, Antoine, Rubio, Maria Jesús, Fariñas-Madrid, Lorena, Lorusso, Domenica, Ray-Coquard, Isabelle, Manso, Luis, Joly, Florence, Alarcón, Jesús, Follana, Philippe, Romero, Ignacio, Lebreton, Coriolan, Pérez-Fidalgo, J Alejandro, Yunokawa, Mayu, Dahlstrand, Hanna, Abadie-Lacourtoisie, Sophie, Anzizar, Nerea, Aoki, Daiseuke, Barretina-Ginesta, Maria-Pilar, Battista, Marco, Bentzen, Anne Gry, Berton, Dominique, Bjørge, Line, Bjurberg, Maria, Bologna, Alessandra, Casanova, Claudia, Chekerov, Radoslav, Chevalier, Annick, Cueva, Juan Fernando, Czogalla, Bastian, Delanoy, Nicolas, Denschlag, Dominik, Derke, Oscar, Eichbaum, Michael, Enomoto, Takayuki, Esteban, Carmen, Fabbro, Michel, Fehm, Tanja, Ferrero, Annamaria, Fleisch, Markus, Floquet, Anne, Frassoldati, Antonio, Gaba, Lydia, Gadducci, Angiolo, García, Yolanda, Geuna, Elena, Hanker, Lars, Hardy-Bessard, Anne-Claire, Harter, Philipp, Hasegawa, Kosei, Hellman, Kristina, Herrero, Ana, Hilpert, Felix, Katsaros, Dionyssios, Koegel, Matthias, Koliadi, Anthoula, Kurtz, Jean-Emmanuel, Lampe, Bjoern, Lissoni, Andrea Alberto, Lortholary, Alain, Mangili, Giorgia, Mansi, Laura, Marmé, Frederik, Mathews, Cara, Mina, William, Nagao, Shoji, Nishino, Koji, Nishio, Hiroshi, Nishio, Shin, Oaknin, Ana, Onstad, Michaela, Pardo, Beatriz, Pisano, Carmela, Poveda, Andrés, Radosa, Julia, Randall, Leslie M., Ray-Coquard, Isabelle, Richardson, Debra, Romero, Ignacio, Ronzino, Graziana, Rubio, Maria Jesús, Selle, Frederic, Takekuma, Munetaka, Takeshima, Nobuhiro, Tewari, Krishnansu, Todo, Yukiharu, Wimberger, Pauline, Woelber, Linn, You, Benoît, Yunokawa, Mayu

Get full text

Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-... by Pujade-Lauraine, Eric, Ledermann, Jonathan A, Selle, Frédéric, Gebski, Val, Penson, Richard T, Oza, Amit M, Korach, Jacob, Friedlander, Michael, Colombo, Nicoletta, Harter, Philipp, Fujiwara, Keiichi, Ray-Coquard, Isabelle, Banerjee, Susana, Liu, Joyce, Lowe, Elizabeth S, Bloomfield, Ralph, Pautier, Patricia, Korach, Jacob, Huzarski, Tomasz, Byrski, Tomasz, Pautier, Patricia, Friedlander, Michael, Harter, Philipp, Colombo, Nicoletta, Scambia, Giovanni, Nicoletto, Maria, Nussey, Fiona, Clamp, Andrew, Penson, Richard, Oza, Amit, Poveda Velasco, Andrés, Rodrigues, Manuel, Lotz, Jean-Pierre, Selle, Frédéric, Ray-Coquard, Isabelle, Provencher, Diane, Prat Aparicio, Aleix, Vidal Boixader, Laura, Scott, Clare, Tamura, Kenji, Yunokawa, Mayu, Lisyanskaya, Alla, Medioni, Jacques, Pécuchet, Nicolas, de la Motte Rouge, Thibault, Lortholary, Alain, Williams, Sarah, Cosin, Jonathan, Hoffman, James, Plante, Marie, Covens, Allan, Sonke, Gabe, Joly, Florence, Hirte, Holger, Park-Simon, Tjoung-Won, Tjulandin, Sergei, Kim, Jae Hoon, Gladieff, Laurence, Sabbatini, Roberto, Timmins, Patrick, Kredentser, Daniel, Laínez Milagro, Nuria, Barretina Ginesta, Maria Pilar, Tibau Martorell, Ariadna, Gómez de Liaño Lista, Alfonso, Ojeda González, Belén, Mileshkin, Linda, Mandai, Masaki, Boere, Ingrid, Ottevanger, Petronella, Nam, Joo-Hyun, Filho, Elias, Hamizi, Salima, Dickson-Michelson, Elizabeth, Kamelle, Scott, McKenzie, Nathalie, Rodriguez, Gustavo, Armstrong, Deborah, Chalas, Eva, Celano, Paul, Davidson, Susan, Welch, Stephen, Fishman, Ami, Bruchim, Ilan, Sikorska, Magdalena, Słowińska, Anna, Rogowski, Wojciech, Bidziński, Mariusz, Śpiewankiewicz, Beata, Casado Herraez, Antonio, Mendiola Fernández, César, Gropp-Meier, Martina, Saito, Toshiaki, Takehara, Kazuhiro, Enomoto, Takayuki, Watari, Hidemichi, Choi, Chel Hun, Kim, Byoung-Gie, Kim, Jae Weon, Vergote, Ignace

Get full text

Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, r... by Poveda, Andrés, Floquet, Anne, Ledermann, Jonathan A, Penson, Richard T, Oza, Amit M, Korach, Jacob, Huzarski, Tomasz, Pignata, Sandro, Friedlander, Michael, Baldoni, Alessandra, Park-Simon, Tjoung-Won, Tamura, Kenji, Lisyanskaya, Alla, Kim, Jae-Hoon, Filho, Elias Abdo, Milenkova, Tsveta, Lowe, Elizabeth S, Rowe, Phil, Pujade-Lauraine, Eric, Korach, Jacob, Huzarski, Tomasz, Byrski, Tomasz, Pautier, Patricia, Harter, Philipp, Colombo, Nicoletta, Pignata, Sandro, Scambia, Giovanni, Nicoletto, Maria, Nussey, Fiona, Clamp, Andrew, Penson, Richard, Rodrigues, Manuel, Lotz, Jean-Pierre, Selle, Frédéric, Ray-Coquard, Isabelle, Provencher, Diane, Prat Aparicio, Aleix, Yunokawa, Mayu, Lisyanskaya, Alla, Medioni, Jacques, Pécuchet, Nicolas, Dubot, Coraline, Kaminsky, Marie-Christine, Weber, Béatrice, Parkinson, Christine, Ledermann, Jonathan, Williams, Sarah, Banerjee, Susana, Cosin, Jonathan, Hoffman, James, Plante, Marie, Covens, Allan, Sonke, Gabe, Joly, Florence, Floquet, Anne, Hirte, Holger, Amit, Amnon, Matsumoto, Koji, Tjulandin, Sergei, Gladieff, Laurence, Sabbatini, Roberto, O'Malley, David, Timmins, Patrick, Kredentser, Daniel, Laínez Milagro, Nuria, Tibau Martorell, Ariadna, Gómez De Liaño Lista, Alfonso, Ojeda González, Belén, Mandai, Masaki, Boere, Ingrid, Ottevanger, Petronella, Nam, Joo-Hyun, Filho, Elias, Hamizi, Salima, Cognetti, Francesco, Warshal, David, Dickson-Michelson, Elizabeth, Kamelle, Scott, Rodriguez, Gustavo, Celano, Paul, Behbakht, Kian, Davidson, Susan, Helpman, Limor, Fishman, Ami, Bruchim, Ilan, Sikorska, Magdalena, Słowińska, Anna, Rogowski, Wojciech, Śpiewankiewicz, Beata, Casado Herraez, Antonio, Mendiola Fernández, César, Saito, Toshiaki, Takehara, Kazuhiro, Enomoto, Takayuki, Watari, Hidemichi, Choi, Chel Hun, Kim, Byoung-Gie, Weon Kim, Jae, Hegg, Roberto, Vergote, Ignace

Get full text

ENDOLUNG trial. A phase 1/2 study of the Akt/mTOR inhibitor and autophagy inducer Ibrilatazar (ABTL0812) in combination with paclitaxel/carboplatin in patients with advanced/recurr... by Leary, Alexandra, Estévez-García, Purificación, Sabatier, Renaud, Ray-Coquard, Isabelle, Romeo, Margarita, Barretina-Ginesta, Pilar, Gil-Martin, Marta, Garralda, Elena, Bosch-Barrera, Joaquim, Morán, Teresa, Martin-Martorell, Paloma, Nadal, Ernest, Gascón, Pere, Rodon, Jordi, Lizcano, Jose M, Muñoz-Guardiola, Pau, Fierro-Durán, Gemma, Pedrós-Gámez, Oriol, Pérez-Montoyo, Héctor, Yeste-Velasco, Marc, Cortal, Marc, Pérez-Campos, Antonio, Alfon, Jose, Domenech, Carles, Pérez-Fidalgo, Alejandro, Oaknin, Ana

Get full text

Correction: ENDOLUNG trial. A phase 1/2 study of the Akt/mTOR inhibitor and autophagy inducer Ibrilatazar (ABTL0812) in combination with paclitaxel/carboplatin in patients with adv... by Leary, Alexandra, Estévez-García, Purificación, Sabatier, Renaud, Ray-Coquard, Isabelle, Romeo, Margarita, Barretina-Ginesta, Pilar, Gil-Martin, Marta, Garralda, Elena, Bosch-Barrera, Joaquim, Morán, Teresa, Martin-Martorell, Paloma, Nadal, Ernest, Gascón, Pere, Rodon, Jordi, Lizcano, Jose M, Muéoz-Guardiola, Pau, Fierro-Durán, Gemma, Pedrós-Gámez, Oriol, Pérez-Montoyo, Héctor, Yeste-Velasco, Marc, Cortal, Marc, Pérez-Campos, Antonio, Alfon, Jose, Domenech, Carles, Pérez-Fidalgo, Alejandro, Oaknin, Ana

Get full text

Risk of endometrial cancer after RRSO in BRCA 1/2 carriers: a multicentre cohort study by Pla-Juher, Helena, Pardo, Marta, Izquierdo, Àngel J., Darder, Esther, Carbó, Anna, Munté, Elisabet, Torres-Esquius, Sara, Balmaña, Judith, Lázaro, Concepción, Brunet, Joan M., Barretina-Ginesta, Maria-Pilar

Get full text

Use of individualized starting dose and niraparib hematologic adverse event management costs in ovarian cancer by Graybill, Whitney S, Vergote, Ignace, Pothuri, Bhavana, Anttila, Maarit, O'Malley, David M, Lorusso, Domenica, Haggerty, Ashley F, Fabbro, Michel, Chan, John K, Heitz, Florian, Willmott, Lyndsay J, Bruchim, Ilan, Zhuo, Ying, Estévez-García, Purificación, Monk, Bradley J, Denys, Hannelore, Knudsen, Anja, Tinker, Anna V, Sánchez, Luis Manso, Provencher, Diane, Barretina-Ginesta, Maria Pilar, Hartman, John, Booth, Donna V, González-Martín, Antonio

Get full text

Correction: ENDOLUNG trial. A phase 1/2 study of the Akt/mTOR inhibitor and autophagy inducer Ibrilatazar (ABTL0812) in combination with paclitaxel/carboplatin in patients with adv... by Leary, Alexandra, Estévez-García, Purificación, Sabatier, Renaud, Ray-Coquard, Isabelle, Romeo, Margarita, Barretina-Ginesta, Pilar, Gil-Martin, Marta, Garralda, Elena, Bosch-Barrera, Joaquim, Morán, Teresa, Martin-Martorell, Paloma, Nadal, Ernest, Gascón, Pere, Rodon, Jordi, Lizcano, Jose M, Muñoz-Guardiola, Pau, Fierro-Durán, Gemma, Pedrós-Gámez, Oriol, Pérez-Montoyo, Héctor, Yeste-Velasco, Marc, Cortal, Marc, Pérez-Campos, Antonio, Alfon, Jose, Domenech, Carles, Pérez-Fidalgo, Alejandro, Oaknin, Ana

Get full text